Ethyl cinnamate
Based on 1 Customer Validation
Ethyl cinnamate, an orally active chemical constituent of the rhizome of Kaempferia galanga, exhibits anti-cancer, nematocidal, sedative and vasorelaxant activities. Ethyl cinnamate is a fragrance ingredient used as a food flavor and additive for cosmetic products. Ethyl cinnamate is also an excellent clearing reagent for mammalian tissues. Ethyl cinnamate suppresses tumor growth through anti-angiogenesis by attenuating VEGFR2 signal pathway in colorectal cancer. Ethyl cinnamate inhibits the tonic contractions induced by high K+ and phenylephrine (PE) with respective IC50 values of 0.30 mM and 0.38 mM in rat aorta.
For research use only. We do not sell to patients.
- Purity : 99.80%
- CAS No.: 103-36-6
- Formula: C11H12O2
- Molecular Weight:176.22
-
Storage:Pure form -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Protocols
- Purity & Documentation
- References
-
Help & FAQs
-
HY-10182
LaduviglusibGSK-3 Inhibitor -
HY-N1363
Royal Jelly acidRoyal Jelly Fatty Acid -
HY-Y0121R
Ethyl cinnamate (Standard)Vascular Relaxant, Nematocide, Tissue Clearing Reagent -
HY-W017212
Methyl cinnamateTyrosinase Inhibitor -
HY-W127330
Butyl LaurateBiochemical Assay Reagent -
HY-N1363R
Royal Jelly acid (Standard)Royal Jelly Fatty Acid -
HY-N1731
2′-Hydroxy-5′-methoxyacetophenoneAnti-inflammatory/Anti-tumor/Anti-mite Agent -
HY-W017212R
Methyl cinnamate (Standard)Tyrosinase Inhibitor
Biological Activity
Description
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| A-375 | IC50 |
31.59 μM
Compound: 7
|
Cytotoxicity against human A375 cells by MTT assay
Cytotoxicity against human A375 cells by MTT assay
|
[PMID: 19782567] |
| A549 | IC50 |
50.35 μM
Compound: 7
|
Cytotoxicity against human A549 cells by MTT assay
Cytotoxicity against human A549 cells by MTT assay
|
[PMID: 19782567] |
| HEp-2 | ED50 |
>50 μg/mL
Compound: Ethyl cinnamate
|
Cytotoxicity against human Hep2 cells assessed a growth inhibition by rapid microtiter technique
Cytotoxicity against human Hep2 cells assessed a growth inhibition by rapid microtiter technique
|
[PMID: 691008] |
| HL-60 | IC50 |
35.69 μM
Compound: 7
|
Cytotoxicity against human HL60 cells by MTT assay
Cytotoxicity against human HL60 cells by MTT assay
|
[PMID: 19782567] |
| HUVEC | IC50 |
95 μg/mL
Compound: 51
|
Antiinflammatory activity against TNF-alpha-induced ICAM1 protein expression in HUVEC pretreated for 2 hrs before TNFalpha challenge measured after 16 hrs by whole cell ELISA
Antiinflammatory activity against TNF-alpha-induced ICAM1 protein expression in HUVEC pretreated for 2 hrs before TNFalpha challenge measured after 16 hrs by whole cell ELISA
|
[PMID: 21955679] |
| THP-1 | IC50 |
41.23 μM
Compound: 7
|
Cytotoxicity against human THP1 cells by MTT assay
Cytotoxicity against human THP1 cells by MTT assay
|
[PMID: 19782567] |
In Vitro
Ethyl cinnamate (0-80 μM, 24 h and 48 h) inhibits VEGF-induced viability, motility, tube formation of Human umbilical vein endothelial cells (HUVECs) in a VEGFR2-dependent manner and induces HUVECs apoptosis[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:HUVECs
-
Concentration:0-80 μM
-
Incubation Time:24 h
-
Result:Significantly inhibited HUVECs proliferation enhanced by vascular endothelial growth factor (VEGF).
-
Cell Line:HUVECs
-
Concentration:0-80 μM
-
Incubation Time:48 h
-
Result:Increased apoptosis rate of cells and decreased the expression levels of Bcl-2/Bax with an IC50 value of 31.79 μM in HUVECs.
In Vivo
Ethyl cinnamate (15, 30, 60 mg/kg, p.o., daily for 21 days) suppresses tumor growth and angiogenesis of HT29 nude mouse colon cancer xenograft model[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Zebrafish embryos[3]
-
Dosage:1-4 μM
-
Administration:incubation, a single dose for 24 h and 48 h
-
Result:Significantly decreased the number of intact intersegmental vessels (ISVs) and inhibited the growth of SIVs in Zebrafish embryos.
-
Animal Model:HT29 nude mouse colon cancer xenograft model[3]
-
Dosage:15, 30, 60 mg/kg
-
Administration:p.o., daily for 21 days
-
Result:Significantly inhibited the tumor growth and inhibited the expression levels of p-VEGFR2, p-Akt, p-ERK1/2, CD34, VEGF and Bcl-2/Bax in a dose-dependent manner in HT29 nude mouse colon cancer xenograft model.
Chemical Information
-
CAS No. 103-36-6
-
Appearance Liquid (Density: 1.049 g/cm3)
-
Molecular Weight 176.22
-
Formula C11H12O2
-
Color Colorless to light yellow
-
SMILES
O=C(OCC)/C=C/C1=CC=CC=C1
-
Structure Classification
-
Initial Source
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Pure form -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Solvent & Solubility
In Vitro:
DMSO : 100 mg/mL (567.47 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
In Vivo:
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (14.19 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (14.19 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Protocols
-
Human pluripotent stem cell endothelial-cell differentiation
Human pluripotent stem cell endothelial differentiation is based on stepwise developmental patterning: early activation of WNT/GSK3β inhibition promotes mesodermal or vascular progenitor entry, followed by endothelial specification using VEGF-related signaling, BMP4, FGF2, Notch modulation, or cAMP depending on the published protocol. Endothelial differentiation is read out by acquisition of CD31, CD34, VE-cadherin/CD144, KDR/VEGFR2, vWF, Tie2, NOS3, acetylated LDL uptake, tube/network formation, barrier function, and in vivo vessel-forming capacity where tested.
-
Vascular/Branching Fractal Analysis
Vascular/branching fractal analysis quantifies the geometric complexity of vessel trees or vascular networks from segmented 2D images, commonly by converting vessels into binary and/or skeletonized maps and estimating fractal dimension using box-counting or related approaches. Fractal dimension is interpreted as an image-derived readout of vascular branching complexity, space filling, or density, and has been applied to retinal photographs, fluorescein angiography, OCT angiography, capillary perfusion maps, and in vitro Matrigel angiogenesis networks. The assay readout is generated from vessel-positive pixels after image preprocessing, vessel segmentation, binarization, and optional skeletonization; reported outputs include fractal dimension, vessel density, branchpoint density, endpoint density, vessel length density, tortuosity, and generation-based branching metrics when VESGEN-style analysis is used. The biological interpretation is limited to quantitative vascular patterning and s
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Patient-Derived Xenograft (PDX)
Patient-derived xenograft (PDX) models are generated by engrafting primary human tumor tissue directly into immunodeficient mice, allowing in vivo propagation of patient tumor biology without initial in vitro adaptation. These models are used to preserve key histopathological and molecular characteristics of the original tumor and enable assessment of tumor growth dynamics and therapeutic response in a living organism. The biological readout is tumor engraftment and subsequent growth in the murine host, which reflects the ability of human tumor cells to survive, vascularize, and expand in an immunocompromised microenvironment.
-
Endothelial Tube Formation Assay
Endothelial tube formation assay evaluates the ability of endothelial cells to attach, migrate, align, and organize into capillary-like networks when cultured on gelled basement membrane extract or Matrigel; the readout is the morphology and quantity of tube-like networks, which reflects an in vitro endothelial morphogenesis step related to angiogenesis. Basement membrane extract/Matrigel provides laminin-rich extracellular matrix cues that support endothelial differentiation into capillary-like structures, but it can contain biologically active growth factors, so growth-factor-reduced matrix is preferred when testing defined angiogenic stimulators or inhibitors.
-
Patient-Derived Orthotopic Xenograft (PDOX)
Patient-derived orthotopic xenograft (PDOX) modeling implants fresh patient tumor tissue or patient-derived tumor cells into the anatomically corresponding organ or tissue site of immunodeficient mice, usually by surgical orthotopic implantation, to preserve patient tumor histology, local microenvironmental context, invasion, metastatic behavior, and treatment-response features better than subcutaneous implantation. PDOX readouts include tumor engraftment, orthotopic tumor growth, local invasion, metastasis, recurrence after resection, histologic similarity to the donor tumor, biomarker retention, molecular concordance, survival, and response or resistance to therapy. PDOX models are used for preclinical drug testing and individualized therapy evaluation, but engraftment success varies by tumor type and specimen quality.
-
Subcutaneous Cell-Line-Derived Xenograft
Subcutaneous cell-line-derived xenograft (CDX) models are established by implanting cultured human cancer cell lines into immunodeficient mice, where the injected cells form localized tumors that can be monitored in vivo as a measure of tumorigenic potential, growth kinetics, and treatment response. These models are widely used in oncology research because they allow reproducible tumor formation and enable comparative assessment of tumor growth between different cell lines or genetic manipulations in a controlled in vivo microenvironment. Subcutaneous implantation of cancer cells in immunodeficient mice is a standard approach for evaluating tumor growth behavior and therapeutic response across multiple cancer types, including prostate, esophageal, pancreatic, and colon cancer models.
-
Orthotopic Cell-Line Xenograft
Orthotopic cell-line xenograft models involve implantation of human cancer cell lines into the anatomically corresponding organ of immunodeficient mice to reproduce tumor growth within a native microenvironment, enabling more clinically relevant tumor behavior compared with subcutaneous models. These models are widely used because orthotopic placement better recapitulates tumor progression, including invasion and metastatic spread, which are often underrepresented in heterotopic implantation systems. Compared with conventional xenografts, orthotopic implantation is described as more technically complex but provides improved simulation of tumor-microenvironment interactions and metastatic behavior, making it particularly valuable for translational oncology research. Surgical orthotopic implantation approaches have been emphasized as enabling faithful reproduction of clinical cancer features, including metastasis and disease progression patterns that align with the tumor’s organ of origi
-
Endothelial Cell Migration/Angiogenic Sprouting Assay
Endothelial cell migration and angiogenic sprouting assays are in vitro (and partially ex vivo-adapted) functional models that quantify the ability of endothelial cells to undergo coordinated migration, extracellular matrix invasion, and multicellular organization into capillary-like sprouts in response to pro-angiogenic stimuli such as VEGF, bFGF, or conditioned microenvironments. These assays are used to model early angiogenic events including tip-cell formation, directional migration, and lumen-like sprout extension, which collectively reflect angiogenic activation and vascular morphogenesis processes observed in vivo.
Purity & Documentation
-
Data Sheet (276 KB)
-
SDS (396 KB)
- English - EN (396 KB)
- Français - FR (396 KB)
- Deutsch - DE (396 KB)
- Norwegian - NO (396 KB)
- Español - ES (396 KB)
- Swedish - SV (396 KB)
- Italian - IT (396 KB)
- Korean - KR (396 KB)
- Portuguese - PT (396 KB)
-
Handling Instructions (2659 KB)
References
[1]. S P Bhatia, et al. Fragrance material review on ethyl cinnamate. Food Chem Toxicol. 2007;45 Suppl 1:S90-4. [Content Brief]
[2]. Anika Klingberg, et al. Fully Automated Evaluation of Total Glomerular Number and Capillary Tuft Size in Nephritic Kidneys Using Lightsheet Microscopy. J Am Soc Nephrol. 2017 Feb;28(2):452-459. [Content Brief]
[3]. Wang S, et al. Ethyl cinnamate suppresses tumor growth through anti-angiogenesis by attenuating VEGFR2 signal pathway in colorectal cancer. J Ethnopharmacol. 2024 May 23;326:117913. [Content Brief]
[4]. Othman R, et al. Vasorelaxant effects of ethyl cinnamate isolated from Kaempferia galanga on smooth muscles of the rat aorta. Planta Med. 2002 Jul;68(7):655-7. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 5.6747 mL | 28.3736 mL | 56.7472 mL | 141.8681 mL |
| 5 mM | 1.1349 mL | 5.6747 mL | 11.3494 mL | 28.3736 mL | |
| 10 mM | 0.5675 mL | 2.8374 mL | 5.6747 mL | 14.1868 mL | |
| 15 mM | 0.3783 mL | 1.8916 mL | 3.7831 mL | 9.4579 mL | |
| 20 mM | 0.2837 mL | 1.4187 mL | 2.8374 mL | 7.0934 mL | |
| 25 mM | 0.2270 mL | 1.1349 mL | 2.2699 mL | 5.6747 mL | |
| 30 mM | 0.1892 mL | 0.9458 mL | 1.8916 mL | 4.7289 mL | |
| 40 mM | 0.1419 mL | 0.7093 mL | 1.4187 mL | 3.5467 mL | |
| 50 mM | 0.1135 mL | 0.5675 mL | 1.1349 mL | 2.8374 mL | |
| 60 mM | 0.0946 mL | 0.4729 mL | 0.9458 mL | 2.3645 mL | |
| 80 mM | 0.0709 mL | 0.3547 mL | 0.7093 mL | 1.7734 mL | |
| 100 mM | 0.0567 mL | 0.2837 mL | 0.5675 mL | 1.4187 mL |
Ethyl cinnamate Related Classifications
HY-Y0121 Related Classifications
Powered by Bioz